"10.1371_journal.pone.0036032","plos one","2012-04-27T00:00:00Z","Munehisa Yabuki; W Jason Cummings; John B Leppard; Robert M Immormino; Christi L Wood; Daniel S Allison; Patrick W Gray; Larry W Tjoelker; Nancy Maizels","Department of Immunology, University of Washington School of Medicine, Seattle, Washington, United States of America; XORI Corporation, Seattle, Washington, United States of America; Accelerator Corporation, Seattle, Washington, United States of America; Department of Biochemistry, University of Washington School of Medicine, Seattle, Washington, United States of America","Conceived and designed the experiments: MY WJC JBL DSA PWG LWT NM. Performed the experiments: MY WJC JBL RMI CLW DSA LWT. Wrote the paper: MY WJC LWT NM. Assisted in writing the manuscript: JBL RMI CLW DSA PWG.","Some authors (MY, WJC, JBL, CLW, DSA, PWG, LWT and NM) declare competing financial interests as they are or have been employed at or are stockholders in XORI Corporation, Omeros Corporation, Boehringer Ingelheim, Alder Biopharmaceuticals or Accelerator Corporation. NM, WJC and MY are inventors of the platform used in this research and described in patent Inducible Mutagenesis of Target Genes (WO2009029315). Patent applications have been filed relating to the anti-FN14 antibodies, the anti-FZD10 antibodies, and the VH targeting method. The authors confirm here that these interests will not alter adherence to PLoS ONE policies on sharing data and materials.","2012","04","Munehisa Yabuki","MY",9,TRUE,7,7,NA,4,TRUE,FALSE,FALSE,0,NA,FALSE
